Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
주식 순위 #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
주가
$4.64
마지막 동기화: 2022-09-12
시가총액
$293.43M
변동 (1일)
0.87%
변동 (1년)
0.00%
국가
US
거래 Adagio Therapeutics, Inc. (ADGI)

카테고리

Adagio Therapeutics, Inc. (ADGI)의 주가 이력
최고 종가: $4.63 (2022-09-01 기준)

최저 종가: $27.68 (2021-08-01 기준)
Adagio Therapeutics, Inc.의 주가 이력 (2021 ~ 2026)
연간 주가 성과
연도 성과
2022 -78.16%
2021 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$121.61 -10.47%
AU
$748.60 6.90%
CH